Thrombosis research最新文献

{"title":"Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial","authors":"Toru Sato , Yoshito Ogihara , Yugo Yamashita , Takeshi Morimoto , Nao Muraoka , Wataru Shioyama , Ryuki Chatani , Tatsuhiro Shibata , Yuji Nishimoto , Kosuke Doi , Maki Oi , Taro Shiga , Daisuke Sueta , Kitae Kim , Yasuhiro Tanabe , Norimichi Koitabashi , Takuma Takada , Satoshi Ikeda , Hitoshi Nakagawa , Kengo Tsukahara , Kaoru Dohi","doi":"10.1016/j.thromres.2026.109631","DOIUrl":"10.1016/j.thromres.2026.109631","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109631"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The distinct etiology and imaging features of pediatric pulmonary embolism: dominance of Mycoplasma pneumoniae-associated in-situ thrombosis and severity risk stratification","authors":"Ruxuan He ,&nbsp;Xiaoyan Zhang ,&nbsp;Xiaolei Tang ,&nbsp;Yuelin Shen ,&nbsp;Hui Liu ,&nbsp;Jinrong Liu ,&nbsp;Huimin Li ,&nbsp;Shunying zhao ,&nbsp;Haiming Yang","doi":"10.1016/j.thromres.2026.109597","DOIUrl":"10.1016/j.thromres.2026.109597","url":null,"abstract":"<div><h3>Background</h3><div>Pediatric pulmonary embolism (PE) incidence has shown a steady rise in recent years, underscoring a distinct and evolving etiological landscape. Infection-related PE, notably <em>Mycoplasma pneumoniae</em> (MPP), now accounts for an increasing proportion of pediatric PE cases, raising questions about a distinct in-situ thrombosis (ISPAT) pathophysiology. We aimed to systematically characterize the etiological spectrum of childhood PE and identify independent predictors of severe disease.</div></div><div><h3>Methods</h3><div>We conducted a 6-year retrospective cohort study of 113 pediatric PE pediatric patients diagnosed with PE at Department No.2 of Respiratory Medicine, Beijing Children's Hospital, from June 2018 to June 2024. Data included clinical and imaging findings, underlying conditions, and outcomes. Predictors of severe PE were assessed using multivariable logistic regression.</div></div><div><h3>Results</h3><div>The median age was 8.37 years. Infection was the leading etiology (89.4%), most commonly MPP (88.1%). Computed tomography pulmonary angiography (CTPA) revealed emboli were predominantly subsegmental/peripheral (80.5%), supporting the ISPAT phenotype. Post-infectious pulmonary vasculitis was identified in 8 patients, with NOD2, MPEG1, or CYBB variants detected in 3 cases. On multivariable analysis, infection−associated PE was independently linked to lower odds of severe PE (adjusted OR 0.12, 95% CI 0.03–0.54; <em>p</em> = 0.0055).</div></div><div><h3>Conclusion</h3><div>Pediatric PE is predominantly an ISPAT phenomenon driven by MPP-associated immunothrombosis. The distinct thrombotic pattern and better prognosis in the infection group support etiology based risk stratification. Furthermore, the observed links with post-infectious vasculitis and variants in NOD2, MPEG1, or CYBB suggest that occult immune dysregulation may modulate thrombotic risk in susceptible children.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109597"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mild hemophilia B in a female with compound heterozygous FIX variants presented with abdominal pain and diagnosed with nutcracker syndrome, and median arcuate ligament syndrome","authors":"Davut Ünsal Çapkan ,&nbsp;Asmin Çelik ,&nbsp;Uğur Gümüş ,&nbsp;İbrahim Tayfun Şahiner ,&nbsp;Ekrem Ünal","doi":"10.1016/j.thromres.2026.109594","DOIUrl":"10.1016/j.thromres.2026.109594","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109594"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146081687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"von Willebrand factor in hemodialysis patients. Does acquired von Willebrand syndrome occur?","authors":"Michele Marchini","doi":"10.1016/j.thromres.2026.109636","DOIUrl":"10.1016/j.thromres.2026.109636","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction and aims&lt;/h3&gt;&lt;div&gt;von Willebrand factor (vWF) is a multimeric plasma glycoprotein synthesized by endothelial cells and megakaryocytes that has an essential role in the primary hemostasis, in fact, the high-molecular-weight multimers (HMWMs) of vWF are the most effective in mediating platelet binding to the extracellular matrix. Acquired von Willebrand syndrome (AvWS) is a bleeding disorder characterized by the loss of HMWMs of vWF with consequent impaired vWF binding to platelets.&lt;/div&gt;&lt;div&gt;Specific hemodynamic conditions of high vascular shear stress and immunologic diseases are linked to the development of this syndrome. Data on vWF function and its multimeric pattern in maintenance hemodialysis patients are scant and inconsistent.&lt;/div&gt;&lt;div&gt;The aim of this study was to investigate the potential development of biochemical markers of AvWS and to preliminarily explore whether the reduction of HMWMs may be associated with an increased risk of bleeding.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Sodium citrate plasma was collected from 53 hemodialysis patients (HP) and 25 healthy control subjects (C). Plasma levels of von Willebrand factor Antigen (vWF:Ag) were measured, and vWF functional activity was assessed by evaluating its Ristocetin cofactor activity (vWF:Rcof).&lt;/div&gt;&lt;div&gt;A vWF:Rcof/vWF:Ag ratio of &lt;0.7 was considered indicative of dysfunctional vWF.&lt;/div&gt;&lt;div&gt;von Willebrand Multimers were separated using sodium dodecyl sulfate (SDS)-agarose low-resolution gels and blotted onto a nitrocellulose membrane. Multimer separation was performed based on electrophoretic mobility. Multimers were detected immunologically using rabbit anti-human-vWF antibodies. Densitometric analysis of multimers and quantification of the percentage of different electrophoretic areas were performed using ImageJ software (NIH, USA). Acquired von Willebrand syndrome (AvWS) was diagnosed if the vWF:Rcof/vWF:Ag ratio was below the normal range (&lt;0.7) and densitometric analysis revealed a reduction HMWMs in hemodialysis patients (HP) compared to controls (C). To quantitatively estimate HMWMs loss, a control-derived threshold was established based on the 5th percentile of the control population (9%). Bleeding events in hemodialysis patients were retrospectively collected from the initiation of dialysis and classified according to ISTH criteria. Corresponding HMWMs levels and vWFRcof/vWF:Ag ratio values were analyzed by means of binary logistic regression. Statistical analysis was performed using MedCalc software (MedCalc Software Ltd., Ostend, Belgium). The alpha value for statistical significance was set at 0.05.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;vWF:Ag levels were higher in HP compared to controls 169.3% (77.9–238.0) vs. 120.8% (82.3–141.6); &lt;em&gt;p&lt;/em&gt; = 0.017. Hemodialysis patients (HP) exhibited also lower vWF:Rcof values to Controls, but this difference was not statistically significant 88.7% (30–148.2) vs. 105.2% (96.1–113.6); &lt;em&gt;p&lt;/em&gt; = 0.16","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109636"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world evaluation of the safety of edoxaban in frail older adults with non-valvular atrial fibrillation","authors":"Alvaro Hermida-Ameijeiras ,&nbsp;Nestor Vazquez-Agra ,&nbsp;Carlos Rodriguez-Pascual ,&nbsp;Bernardo-Abel Cedeno-Veloz ,&nbsp;Ramon Baeza-Trinidad ,&nbsp;Pablo Solla-Suarez ,&nbsp;Juan-Bosco Lopez-Saez ,&nbsp;Ricardo Gomez-Huelgas ,&nbsp;Santiago-Jesus Freire-Castro ,&nbsp;Alicia Balanza-Garzon ,&nbsp;Cristina Roqueta ,&nbsp;Antonio Pose-Reino","doi":"10.1016/j.thromres.2026.109614","DOIUrl":"10.1016/j.thromres.2026.109614","url":null,"abstract":"<div><h3>Background</h3><div>Despite available observational data and post hoc analyses, the underprescription of DOACs in frail older adults and their underrepresentation in randomized trials have resulted in a still limited evidence base.</div></div><div><h3>Objective</h3><div>To evaluate the safety of edoxaban in frail older patients in routine clinical practice in Spain.</div></div><div><h3>Materials and methods</h3><div>EDO-FRAG-001 was a multicenter, prospective, observational, real-world, single-cohort study with 12 months of follow-up. Patients aged ≥75 years with non-valvular atrial fibrillation (NVAF), a FRAIL scale score between 3 and 5, and those who initiated edoxaban within the previous 6 months were enrolled.</div></div><div><h3>Results</h3><div>A total of 411 patients (63% women) were included, with a median age of 87 years. Fifty-five percent had previously received vitamin K antagonists. Edoxaban was prescribed according to the drug label in 89.1% of patients. During follow-up, 31 patients experienced major bleeding events [annualized rate: 8.7% (95% CI: 5.8–11.6)], and 5 individuals developed an ischemic stroke or systemic embolism [1.1% (95% CI: 0.1–2.2)]. One-year all-cause mortality was 18.8% (95% CI: 15.1–22.5), and cardiovascular mortality accounted for 8.7% (95% CI: 6.2–11.2). The incidence of bleeding-related death was 2.0% (95% CI: 0.5–3.5).</div></div><div><h3>Conclusion</h3><div>This real-world study supports that the use of edoxaban in frail older adults with NVAF is associated with an acceptable rate of bleeding and stroke. Age and frailty alone should not preclude anticoagulation when treatment is carefully individualized.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109614"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146166765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of cerebral venous sinus thrombosis due to essential thrombocythemia: Current status and future perspectives","authors":"Zexun Liu ,&nbsp;Yuanyuan Xiang ,&nbsp;Changlin Xie ,&nbsp;Xiaoping Yin ,&nbsp;Manqing Zhang ,&nbsp;Zhiying Chen","doi":"10.1016/j.thromres.2026.109613","DOIUrl":"10.1016/j.thromres.2026.109613","url":null,"abstract":"<div><div>Essential Thrombocythemia (ET) is a myeloproliferative neoplasm driven by JAK2V617F, CALR, and MPL mutations, characterized by persistent thrombocytosis and hypercoagulability. Cerebral Venous Sinus Thrombosis (CVST) represents a severe complication of ET, yet the underlying mechanisms remain unclear. Genetically, the JAK2V617F mutation activates the JAK-STAT pathway, inducing platelet hyperactivation, neutrophil extracellular trap formation, and the release of platelet-derived microparticles, which alter blood rheology and promote thrombosis. Mutations in CALR and MPL accelerate megakaryopoiesis, while erythrocyte dysfunction exacerbates hyperviscosity. Anatomical variations in the cerebral venous sinuses synergize with these abnormalities to create a prothrombotic microenvironment. Diagnostically, MRI/MRV is the first choice, with the primary challenge being the differentiation of venous sinus hypoplasia from thrombosis in ET patients, combined with the detection of the JAK2 mutation for confirmation. This review summarizes the genetic and cellular mechanisms linking ET to CVST, discusses tailored diagnostic strategies and therapies (JAK inhibitors, anticoagulants), and highlights the need for further research to clarify the interplay between molecular abnormalities and vascular factors, aiming to optimize clinical management.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109613"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism prevention in ambulatory oncology: A multi-method evaluation of the Vermont Model to inform adaptation to an oncology-delivered model","authors":"Karlyn A Martin ,&nbsp;Emily Hallgren ,&nbsp;Chris E Holmes ,&nbsp;Jacob Barker ,&nbsp;Lisa R. Hirschhorn ,&nbsp;Kenzie A. Cameron","doi":"10.1016/j.thromres.2026.109610","DOIUrl":"10.1016/j.thromres.2026.109610","url":null,"abstract":"<div><h3>Background</h3><div>Despite evidence-based guidelines, venous thromboembolism (VTE) prevention in ambulatory cancer remains low. The “Vermont Model” is a multidisciplinary program wherein oncology nurses conduct VTE risk assessment, VTE patient-education to all patients starting anti-cancer therapy and refer high risk patients to thrombosis specialist to discuss thromboprophylaxis. The Vermont Model successfully improved targeted anticoagulation prophylaxis for high-risk patients, but efforts to reproduce the model in community oncology practices were less successful. The objective of this study was to evaluate stakeholder (clinician and patient) perceptions of the Vermont Model to inform adaptation to a fully oncology-delivered approach.</div></div><div><h3>Methods</h3><div>We conducted a concurrent multi-method study from September 2024–January 2025, including a clinician survey assessing normalizing of the Vermont Model into clinical practice and semi-structured interviews of participating clinicians and patients.</div></div><div><h3>Results</h3><div>Ten clinicians and four patients completed interviews. Based on 9 clinician surveys, the Vermont Model is normalized into practice. Factors important to its success reflected in both the survey and interviews data included a strong culture valuing VTE prevention and a local champion. Participants supported a fully oncology-delivered model, yet challenges to success include lapses in intervention education/training, communication among health care team, and relative priority with existing workload.</div></div><div><h3>Conclusion</h3><div>We found high normalization of the Vermont Model among participating clinicians and highlight opportunities to enhance training, education, and interprofessional communication to scale out to a fully oncology-delivered model.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109610"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Methodological considerations for diagnostic test accuracy meta-analyses","authors":"Javier Arredondo Montero","doi":"10.1016/j.thromres.2026.109629","DOIUrl":"10.1016/j.thromres.2026.109629","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109629"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of institutional thrombophilia guidelines and electronic medical record tools to reduce inpatient thrombophilia testing and costs","authors":"Muhammad Mubbashir Sheikh ,&nbsp;Hatim Attar ,&nbsp;Diane Book ,&nbsp;Kristen Corrao ,&nbsp;Ashley Cunningham ,&nbsp;Joshua J. Field ,&nbsp;Patrick Foy ,&nbsp;Alexandra M. Harrington ,&nbsp;Jacob Janssen ,&nbsp;Benjamin Jung ,&nbsp;Julie Kolinski ,&nbsp;Nathan Ledeboer ,&nbsp;Jennifer McIntosh ,&nbsp;Siddhartha Singh ,&nbsp;Lisa Baumann Kreuziger","doi":"10.1016/j.thromres.2026.109632","DOIUrl":"10.1016/j.thromres.2026.109632","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109632"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer","authors":"J.T. Buijs ,&nbsp;N. van Es ,&nbsp;C. Englisch ,&nbsp;R.J.S. Anijs ,&nbsp;F.T.M. Bosch ,&nbsp;B.J.M. van Vlijmen ,&nbsp;F.I. Mulder ,&nbsp;I. Pabinger ,&nbsp;C. Ay ,&nbsp;H.H. Versteeg ,&nbsp;Y. Mohammed","doi":"10.1016/j.thromres.2026.109612","DOIUrl":"10.1016/j.thromres.2026.109612","url":null,"abstract":"<div><div>Cancer patients have an eleven-fold increased risk of venous thromboembolism (VTE) compared to the general population. In this hypothesis-generating study we investigated plasma protein levels in colorectal cancer patients with and without thrombosis using targeted absolute quantification of 269 plasma proteins. We included samples from 142 patients with stage III/IV colorectal cancer from MICA – a multinational prospective cohort study, and from 98 patients from CATS – a prospective cohort study with stage III/IV colorectal cancer. The primary outcome was objectively confirmed symptomatic or incidental deep vein thrombosis or pulmonary embolism during a 6-month follow-up period. In MICA, 11 (7.7%) developed VTE; in CATS 6 patients (6.1%) developed VTE within 6 months, and 10 (10.2%) within 2 years.</div><div>Six differentially abundant proteins (DAPs) were identified in MICA: APOB100, CD5L, IGHG1, IGHM, PRG4, and TF. A model using these six proteins achieved a c-statistic of 0.687 (95% CI: 0.658–0.717) by internal cross-validation with 100 repeats and random 80% training sets. The optimism-corrected c-statistics was 0.675 (95% CI: 0.648–0.701). Using any subset of the DAPs yielded a c-statistics &gt;0.67, with the best model reaching 0.768 (95% CI: 0.746–0.790). This outperformed the Khorana, modified-Vienna, PROTECHT, and CONKO models. The six DAPs had also predictive value in CATS with c-statistics at 0.70 (95% CI:0.671–0.728) for the 6-month, and 0.73 (95% CI:0.702–0.728) for 2-year follow-up. Two proteins showed inverted patterns between cohorts, likely due to chemotherapy. Our findings call for further investigation into the proteins identified, warranting further validation in larger, standardized studies.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109612"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}